3 Brexit ‘buys’: AstraZeneca plc, Compass Group plc and Severn Trent plc

These three stocks offer stunning long-term growth prospects in a post-Brexit world: AstraZeneca plc (LON: AZN), Compass Group plc (LON: CPG) and Severn Trent plc (LON: SVT).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One of the appealing aspects of buying utility stocks such as Severn Trent (LSE: SVT) is their performance during crises. In such periods, investors normally switch from a risk-on attitude to a risk-off one and seek out safer places to invest their capital. Utilities, with their robust earnings outlooks and stable business models, have huge appeal. Therefore, it’s of little surprise that Severn Trent’s shares have outperformed the FTSE 100 since the EU referendum.

Looking ahead, further outperformance could be on the cards. That’s because the outlook for the UK economy is highly uncertain and the trend described above may continue over the medium-to-long term. Furthermore, Severn Trent could also be viewed as a more obvious bid target in the coming months as the value of sterling plummets and it becomes cheaper and therefore more attractive for foreign bidders to acquire the water services company.

As well as a defensive profile and bid potential, Severn Trent also has a beta of just 0.7. This indicates that it offers a less volatile shareholder experience, thereby increasing its appeal in a post-Brexit world further still.

Navigating through tough times

Also offering a highly defensive profile is food services business Compass Group (LSE: CPG). It’s a highly efficient, well-run company which is able to demonstrate a long track record of having delivered rapidly rising earnings growth. Due to the uncertainty present in markets at the moment, this relative certainty could be worth an even greater premium than usual and Compass shares may significantly outperform the wider index.

One of the main drivers of Compass’ share price in recent years has been its dividend growth. In fact, it has risen at an annualised rate of 11% during the last five years, which is clearly well ahead of inflation. Next year, Compass is expected to grow dividends by around 10% and yet shareholder payouts are still set to equate to just 55% of profit. This indicates that further rapid dividend growth is ahead to boost its current yield of 2.3%.

Post-Brexit shot in the arm?

Living in a post-Brexit world could also be made easier by investing in AstraZeneca (LSE: AZN). That’s because the key driver of its share price in the coming years is unlikely to be the political or economic challenges faced by the UK, but rather the company’s ability to transition from having a strong pipeline to having multiple blockbuster drugs.

Although there’s no guarantee that this will happen, AstraZeneca seems to be doing all of the right things to boost its top and bottom line performance. Its acquisition programme is likely to remain ambitious, while it remains a relatively efficient business that’s investing heavily in its own research capabilities.

Due to its strong cash flow, AstraZeneca has been able to keep dividends at a generous level in recent years so that it yields 4.4% right now, even though its profitability has fallen. This income stability, plus the scope for rapidly rising dividends and a low correlation with the macroeconomic outlook, mean that AstraZeneca could be an excellent ally in an uncertain post-Brexit period.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and Severn Trent. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »

Investing Articles

£13,200 invested in this defensive stock bags me £1K of passive income!

Building a passive income stream is possible and this Fool breaks down one investment in a single stock that could…

Read more »

Investing Articles

I think the Rolls-Royce dividend is coming back – but when?

The Rolls-Royce dividend disappeared in 2020 and has not come back. But with the company performance improving, might it reappear?

Read more »

British Pennies on a Pound Note
Investing Articles

Should I snap up this penny share in March?

Our writer is considering penny shares to buy for his portfolio next month. Does this mining company merit a place…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Stock market bubble – or start of a bull run?

Christopher Ruane considers whether the surging NVIDIA share price could be symptomatic of a wider stock market bubble forming.

Read more »

Investing Articles

Buying 8,254 Aviva shares in an empty ISA would give me a £1,370 income in year one

Harvey Jones is tempted to add Aviva shares to his Stocks and Shares ISA this year. Today’s 7.37% yield isn't…

Read more »

Investing Articles

Is the tide turning for bank shares?

Bank shares are trading on stubbornly cheap-looking valuations yet business performance in the sector is broadly robust. Should our writer…

Read more »